Astral renal stenting trial pdf

The overall finding of the coral trial was that stenting of atherosclerotic renal artery ste noses did not reduce the composite end point. Astral started recruiting in november 2000 and, as of the end of 2006, 731 patients have been randomized into the trial 19 patients. The conclusion of the astral trial should be that if you, as a wise doctor, think or feel that a patient needs to be treated with a stent, you should do so, but if you are uncertain, which seems to be rare looking at the astral inclusion data, the patient should get best medical treatment. The angioplasty and stenting for renal artery lesions astral investigators found substantial. Endovascular treatment for atherosclerotic renal artery stenosis aras was. The astral trial also was published in 2009 but was a larger study, including 806 patients with atherosclerotic renal artery stenosis randomly assigned to percutaneous transluminal renal artery angioplasty with or without stent placement plus medical treatment or to medical treatment alone, with 403 patients in each arm. Effect of renal artery stenting on renal function and size in. Does renal artery stenting prevent clinical events. Clinical and kidney morphologic predictors of outcome for. The angioplasty and stent for renal artery lesions astral trial comparing renal function in arvd patients randomized to either revascularization or. Pdf the astral trial results revisitedto stent or not. Randomized clinical trial testing the effect of renal artery stenting versus medical therapy on left ventricular hypertrophy progression in patients affected by ischemic heart disease and renal artery. Clinical outcome of renal artery stenting for hypertension.

Patients were screened for enrollment in the study. Stents no benefit in renalartery stenosis medscape. Renal artery stenting, as compared to medical therapy, does not reduce the incidence of cardiovascular or renal events among patients with atherosclerotic renal artery stenosis, according to results of the coral trial presented nov. Angioplasty and stent for renal artery lesions trial astral.

The astral trial, which was performed with the goal of determining whether stenting of the renal artery renal artery percutaneous angioplasty and stenting raptas combined with best medical therapy improved renal function and other outcomes when compared with best medical therapy alone. Initial results from the astral angioplasty and stenting for renal artery lesions trial. White, md the subject of renal artery stenting has received considerable attention with the release of the results of the coral trial. Disease study equation also are nearly ubiquitous in this population. In this trial, 806 patients with atherosclerotic renal artery stenosis were randomized to either. Renal artery stenting in patients with uncontrolled. One seriously flawed study of renal stenting after another. The astral study was widely criticized on several grounds, 1, 2, 3 which led to questioning its main conclusion that percutaneous transluminal. Stents no help in renal artery stenosis medpage today. Cardiovascular outcomes in renal atherosclerotic lesions.

Although revascularization does not benefit most pa. The angioplasty and stenting for renal artery lesions astral trial is the largest trial to date into treatment for the kidney condition, it considered whether there is any real benefit to a combined approach of revascularisation treatment and medical therapy, compared with just medical therapy alone. Primary stenting for atherosclerotic renal artery stenosis. There still are indications for renal artery stenting after coral. Astral trial results revisitedto stent or not to stent in. Stenting for renal artery atherosclerosis has soared in popularity since the 1990s. Likewise, two randomized studies published in 2009 the astral trial and the star trial failed to show a clear benefit for renal artery stenting with respect to kidney function the newly.

Revascularization versus medical therapy for renalartery. In the astral study, data were presented for the more affected kidney for which. Atherosclerotic renal artery stenosis and renal artery. A few small randomized trials began in the late 1990s to determine a competitive advantage of angioplasty for ras.

Despite these technical improvements, the indications for renal artery stenting are still a matter of debate due to the unproven benefit of renal revascularisation compared with best medical therapy, 3,22,23 including the recently presented results of the astral trial angioplasty and stent for renal artery lesion 24 and the star trial. Systematic study of the effects of renal intervention upon the heart has never previously been undertaken, so assessment of whether or not. There still are indications for renal artery stenting. Revascularization for atherosclerotic renal artery.

Angioplasty and stent for renal artery lesions astral trial. Coral cardiovascular outcomes in renal atherosclerotic lesions 35 is the largest ongoing trial on renal artery stenting, with 1,080 patients randomly allocated to stenting with medical therapy versus medical therapy alone. Methods using data from 947 patients with a history of hypertension or chronic kidney disease from the largest randomized trial of renal artery stent placement, the coral cardiovascular outcomes in renal atherosclerotic lesions study, we performed exploratory analyses to determine if subsets of patients experienced better outcomes after stent placement than the overall cohort. Both trials showed no evidence of benefit in renal function or blood pressure reduction. Systematic study of the effects of renal intervention upon the heart has never previously been undertaken, so assessment of whether or not renal. The angioplasty and stenting for renal artery lesions astral study 10 was a similar comparison with similar results, showing no benefit from stenting with respect to renal function, systolic blood pressure control, cardiovascular events, or death. Astral angioplasty and stent for renal artery lesions possibly the most debated trial thats not yet published. The angioplasty and stenting for renal artery lesions astral trial 20 was designed to address several questions, but most importantly to determine reliably whether revascularization together with best medical therapy improves renal function and other outcomes as compared with medical therapy alone in patients with. Does stenting of severe renal artery stenosis improve. Investigators in the angioplasty and stenting for renal artery lesions astral trial are listed in the supplementary appendix, available with the full text of this article at.

Pdf angioplasty and stent for renal artery lesions astral trial. Update on intervention versus medical therapy for atherosclerotic. Older renal artery trials, for example star stent placement in patients with. Renal artery stenting is no longer indicated after. The enrollment criteria addressed some of the weaknesses faced in star and astral. Astral trial reported higher creatinine values at 5 years for both the stenting. Renal artery stenosis can lead to several different clinical syndromes ranging from difficult to control hypertension to recurrent pulmonary edema shortness of breath due to the lungs filling with fluid to ischemic nephropathy kidney dysfunction due to compromised arterial blood flow and frank renal failure. Lookat star,astral primaryendpoint renal functionyet manyhadunilateral. Do patients undergoing renal revascularization outside of. Various study results suggest that patients with baseline or more severe renal. The angioplasty and stenting for renal artery lesions astral investigators found substantial risks without evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease. In 2014, the society for cardiovascular angiography and interventions scai released a new expert consensus statement for the appropriate use of renal artery stenting. The clinical data have resulted in less widespread acceptance of the benefits of renal artery stenting. Pdf angioplasty and stent for renal artery lesions.

Strengths and limitations of renal artery stenting trials and a look at whats next in this arena. It has been hypothesized that ras is a potentially reversible cause of hypertension and these other sequelae, and the. Mistry s, ives n, harding j, et al angioplasty and stent for renal artery lesions astral trial. Below we will describe the landmark trials that have guided us to our current belief in optimal treatment for our patients with ras. Approval has been gained for long term astral followup. Renal artery stenosis ras occurs in up to 5% of people with hypertension and is associated with ischemic nephropathy and other complications. Astral trial results revisitedto stent or not to stent in renal artery. The angioplasty and stenting for renal artery lesions astral investigators found substantial risks without evidence of a worthwhile clinical benefit from revascularization in patients with. The angioplasty and stent for renal artery lesions astral trial comparing renal function in arvd patients randomized to either revascularization or medical management alone was designed to. Astral finds no benefit from renal stenting the renal. Effect of renal artery stenting on left ventricular mass.

The uncertain value of renal artery interventions core. Angioplasty and stenting for renal artery lesions astral trial was designed to determine reliably whether revascularization together with medical therapy improves renal function and other outcomes, as compared with medical ther apy alone, in patients with atherosclerotic renal. We believe that the unconventional study design and significant methodologic flaws of this trial led to inaccurate. The astral trial opened in september 2000 and closed in october 2007 having recruited 806 patients, making it by far the largest trial in atherosclerotic. The coral trial compared the incidence of cardiovascular and renal adverse events for medical therapy alone with medical therapy plus renalartery stenting in patients with atherosclerotic renalartery stenosis and elevated blood pressure, chronic kidney disease, or both. Data from the angioplasty and stenting for renal atherosclerotic lesions trial conducted over nearly the same time interval indicate that mortality was in excess of 25% in the cohort compared with 4. The future of renal artery stenting for atherosclerotic renal artery stenosis recently, the coral trial was published 1. The astral trial in the angioplasty and stenting for renal artery lesions astral trial,8 the primary outcome measure was the change in renal function over time as assessed by the mean slope of the reciprocal of the serum creatinine. The astral trial was a multicenter, randomized, unblinded clinical trial including a total of 806 patients 1. The primary comparison was the rate of decline of renal function based on individual reciprocal creatinine plots for the periods leading up to and following revascularization. The angioplasty and stenting for renal artery lesions astral trial was designed to determine reliably whether revascularization together with medical therapy improves renal function and other. Indeed, the astral investigators acknowledged that the results of a large trial may disguise a worthwhile. Chakraverty, do patients undergoing renal revascularization outside of the astral trial show any benefit.

Influence and critique of the astral and coral trials. The coral trial demonstrated that subjects with ras had similar outcomes whether randomized to optimal medical therapy alone or. Stent placement in patients with atherosclerotic renal. Astral angioplasty and stenting for renal artery lesions trial was longitudinal change in renal function, while that of the coral cardiovascular outcomes in renal atherosclerotic lesions trial was a composite of death or major morbidity from cardiovascular or renal causes 5, 6. Revascularization versus medical therapy for renalartery stenosis. The results of the angioplasty and stenting for renal artery lesions astral trial were released in 2009. Landmark trials in renal artery stenosis renal fellow. Now an nhlbisponsored trial makes it clear, there are no advantages to the intervention. To determine the efficacy and safety of stent placement in patients with aras and impaired renal function. The investigators of the recently published astral angioplasty and stenting for renal artery lesions trial concluded that there was substantial risk without worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease.

Astral does not plug gap in renal stenting evidence. Cardiac structure and function after revascularization. Pdf atherosclerotic renovascular disease arvd is a relatively common condition which may lead to progressive renal dysfunction, and. Results of the major randomized clinical trials of renal. Little is known about the efficacy and safety of renal artery stenting in patients with atherosclerotic renal artery stenosis aras and impaired renal function. The landmark astral trial, published in the nejm this week, failed to demonstrate benefit from renal artery stenting in most patients with atherosclerotic renal artery stenosis. Angioplasty and stent for renal artery lesions astral. The astral trial is designed to address the issue of whether renal arterial revascularisation with balloon angioplasty andor endovascular stenting can safely prevent progressive renal failure among a wide range of patients with arvd. From the 1990s to coral cardiovascular outcomes in renal. The star trial investigated renal artery stenting in 140 patients with impaired renal function creatinine clearance arteries. The future of renal artery stenting open access journal. Whether renal revascularization reduces left ventricular hypertrophy in patients with coronary artery disease is uncertain.

762 168 452 827 742 1001 1369 1426 715 512 243 1268 1564 1030 466 665 1436 1392 564 1011 673 752 151 1004 336 387 1038 13 243 1364 462 1483 292 682 1528 370 587 271 857 512 1159 291 86 1179 241 193 1428